BioBridgeX
Log inCompare quotes
Indication

Pediatrics CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Pediatric drug development means adapting a program for children: juvenile toxicology, age-appropriate formulations, pediatric-specific PK and dosing, and trials run under FDA PSP/RACE and EMA PIP rules. CROs and CDMOs supply juvenile animal studies, taste-masked and low-dose formulation work, and trial sites with pediatric access. On BioBridgeX, buyers source and compare qualified vendors under one contract, free for buyers.

Pediatrics CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Pediatrics CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does a Pediatrics program need?

Pediatrics is not a disease, it is a population, and that changes what you outsource. A pediatric program almost always sits on top of an adult indication: you are extending an asset into children, which means the science has to account for the fact that a child is not a small adult. Organ systems mature on their own timeline, drug-metabolizing enzymes switch on and off across infancy, body composition shifts, and the dose that works in a 70 kg adult can be wrong by a wide margin in a neonate. The CRO and CDMO work clusters around those differences: juvenile safety, age-appropriate dosing and formulation, and trials that can actually recruit and dose children safely.

On the preclinical side, the centerpiece is the juvenile animal toxicology study. Regulators ask for it when there is a concern that a developing organ system (brain, bone, kidney, reproductive tract) could be affected in ways the adult tox package never sees. A CRO designs the study to dose at the developmental stage that maps to the pediatric age group you are targeting, which means careful selection of species and dosing windows, plus developmental and reproductive readouts. This is GLP work, and the design conversation with the agency (often through a pre-IND or a Pediatric Study Plan meeting) shapes what the CRO actually runs.

Formulation and CMC are where pediatrics gets genuinely hard, and where the CDMO earns its fee. A tablet sized for an adult is useless for a two-year-old. You need an age-appropriate dosage form: an oral liquid, a dispersible or orally disintegrating tablet, mini-tablets, granules or sprinkles, sometimes a flexible dosing platform that covers neonates through adolescents from one product. That pulls in taste-masking (children reject bitter drugs and non-adherence ruins your data), excipient safety (several excipients that are fine in adults are restricted or banned for neonates, such as benzyl alcohol and propylene glycol), low-dose content uniformity, and stability of a liquid or pediatric solid. A CDMO that has shipped approved pediatric formulations is worth more here than a generalist.

On the clinical side, the work is pediatric trial execution: sites with pediatric and neonatal access, investigators and coordinators trained for children, ethics and assent processes, population-PK and modeling-and-simulation to bridge from adult exposure to a pediatric dose (extrapolation and PBPK are central to modern pediatric programs and reduce how many children you have to enroll), pediatric-appropriate endpoints and patient-reported or observer-reported outcomes, and blood-volume-sparing sampling such as microsampling. All of this runs inside a regulatory frame you commit to early: an FDA Pediatric Study Plan under PREA and the RACE for Children Act for oncology molecular targets, and an EMA Paediatric Investigation Plan. Agreeing that plan governs the timing of nearly every study above.

How do you choose a CRO or CDMO for Pediatrics?

The deciding factor in pediatrics is demonstrated pediatric experience, not general competence in the underlying indication. A site that runs flawless adult oncology trials may have no pediatric ward, no pediatric ethics standing, and no track record dosing infants. A formulation group that makes adult tablets may never have validated a taste-masked oral suspension or qualified excipients for neonatal use. Ask for the pediatric work specifically, by age band and by deliverable, and confirm the people you would work with have done it before. Use the checklist below when you put two or three vendors against the same written scope.

  • Pediatric track record by age band: confirm real experience in the age groups you are targeting (neonates, infants, children, adolescents), since a vendor strong in adolescents may have none in neonates, where the science and safety bar are hardest.
  • Regulatory experience with PSP, PIP, PREA, BPCA and the RACE Act: ask whether the CRO has supported an FDA Pediatric Study Plan or an EMA Paediatric Investigation Plan through to agreement, and whether they have handled the RACE for Children Act for an oncology target.
  • Juvenile toxicology design and species selection: for preclinical vendors, confirm GLP juvenile tox capability and that they have matched dosing windows to pediatric developmental stages, with developmental and reproductive readouts.
  • Age-appropriate formulation and excipient safety: for CDMOs, look for shipped pediatric dosage forms (oral liquids, ODTs, mini-tablets, sprinkles), taste-masking experience, and a clear handle on excipients restricted in young children.
  • Pediatric site access and recruitment: confirm relationships with pediatric and neonatal sites, realistic enrollment estimates for a small and protected patient pool, and experience with assent, consent, and pediatric ethics review.
  • PK modeling and extrapolation capability: pediatric programs lean on population PK, PBPK, and modeling-and-simulation to bridge from adult data and minimize pediatric exposure, so confirm the vendor brings real pharmacometrics, not just data collection.
  • Data quality and safety oversight: ask about pediatric-specific safety monitoring, blood-volume-sparing sampling, and how they handle the tighter consent and reporting expectations that come with studying children.
  • Capacity and timeline against the agreed plan: pediatric studies often gate on a committed PSP or PIP timeline, so confirm the vendor can hit those dates and has the queue to do so.

Frequently asked questions

When does a pediatric study become required, and is it optional?
For most programs it is not optional. In the US, PREA requires a pediatric assessment for many new drugs and biologics unless you get a waiver or deferral, and you commit to an FDA Pediatric Study Plan (PSP) early, typically around the end of Phase 2. The RACE for Children Act removed the orphan exemption for certain oncology drugs aimed at molecular targets relevant to pediatric cancers, so many oncology assets now trigger pediatric study requirements that used to be skippable. In the EU, the EMA Paediatric Investigation Plan (PIP) is a parallel obligation. There are also incentives, not just mandates: BPCA offers six months of additional exclusivity for completing requested pediatric studies. Sorting out which apply to your asset, and when, is one of the first things a pediatric-experienced CRO helps you scope.
Why do I need a juvenile animal toxicology study if I already have adult tox data?
Because the adult tox package is run in mature animals and cannot tell you whether a drug harms a developing organ system. Children are not just smaller; their brains, bones, kidneys, and reproductive systems are still developing, and a compound can disturb that maturation in ways that never appear in an adult study. A juvenile tox study doses animals at the developmental stage that corresponds to your target pediatric age group and adds developmental, reproductive, and sometimes neurobehavioral readouts. Regulators ask for it when there is a plausible developmental concern, and the design (species, dosing window, endpoints) is usually agreed with the agency through the pre-IND or PSP process before the CRO runs it under GLP.
What is an age-appropriate formulation, and why can't I just use the adult tablet?
An age-appropriate formulation is a dosage form a child can actually take and that delivers an accurate dose for their size. An adult tablet fails on both counts: a young child cannot swallow it, and you cannot split it down to the small, body-weight-adjusted doses pediatrics needs. So CDMOs build oral liquids, orally disintegrating tablets, mini-tablets, or granules and sprinkles, often as a flexible platform that covers a wide age range. The harder parts are taste-masking, because children reject bitter drugs and non-adherence wrecks your trial data, and excipient safety, because several excipients that are fine in adults are restricted or banned in neonates and infants. Low-dose content uniformity and stability of a liquid round out the work. A CDMO with approved pediatric formulations behind it is a meaningfully safer bet than a generalist.
How does extrapolation reduce the number of children I have to enroll?
Recruiting children is slow, the patient pool is small and protected, and there are ethical limits on how much you can sample from a child. Modern pediatric development leans hard on extrapolation: if the disease and the drug's exposure-response are reasonably similar between adults and children, you can borrow adult efficacy evidence and focus the pediatric work on confirming exposure and safety. Population PK, PBPK modeling, and modeling-and-simulation let you bridge from adult data to a predicted pediatric dose, then verify it with a smaller PK and safety study using blood-volume-sparing sampling. This is why pharmacometrics capability matters when you choose a CRO; a vendor that only collects data and cannot model it leaves the most valuable lever unused.
Do I need different CROs for the preclinical, formulation, and clinical pieces of a pediatric program?
Often yes. Juvenile toxicology, age-appropriate formulation and CMC, and pediatric clinical execution are distinct specialties, and the best vendor for one is frequently not the best for another. A GLP tox lab, a pediatric-experienced CDMO, and a clinical CRO with neonatal site access rarely all live under one roof at the quality you want. That fragmentation is exactly what creates contracting overhead: separate MSAs, POs, and invoices for each. On BioBridgeX you can source and compare each specialist vendor and still sign one contract, raise one purchase order, and receive one invoice across all of them, which keeps the procurement simple even when the science is split across several labs.
Is sourcing a Pediatrics CRO or CDMO on BioBridgeX free for buyers?
Yes. BioBridgeX is free for buyers and acts as a neutral vendor of record, so it has no reason to push you toward a more expensive lab. Vendors pay a flat 2% platform fee. Because a pediatric program usually pulls in several specialists at once (juvenile tox, age-appropriate formulation, and pediatric clinical sites), you can source multiple vendors and still sign one contract, raise one purchase order, and receive one invoice across all of them, with coverage spanning every indication and modality.

Source Pediatrics work with one contract

Compare transparent quotes from qualified Pediatrics CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes